graft-versus-host disease

[Cytotherapy] Human umbilical cord-derived MSCs effectively decreased the incidence and severity of graft-versus-host disease (GVHD), which was mediated by the enrichment of myeloid-derived suppressor cells in GVHD target tissues.

[Stem Cell Research & Therapy] Scientists discuss and explain the most recent advances in chimeric antigen receptor (CAR) T cell-based therapies targeting acute myeloid leukemia (AML) antigens and review the results of preclinical and clinical trials.

[Blood Reviews] Scientists summarize the current knowledge about statins and other agents used as endothelial protectants. They propose further studies using statins for prophylaxis and prevention of end-organ damage related to extensive endothelial dysfunction in hematopoietic stem cell transplantation and chimeric antigen receptor-T cells.

[Immunity Inflammation and Disease] Graft-versus-host disease (GVHD) was induced in lethally irradiated BALB/c mice. M2 macrophages derived from donor bone marrow (BM) were administered intravenously, while controls received donor BM-mononuclear cells and splenocytes.

[Haematologica] Scientists showed that endoplasmic reticulum stress contributed to intestinal tissue injury during graft-versus-host disease and could be targeted pharmacologically.

[Stem Cell Reviews and Reports] Most of the 416 published trials evaluated MSCs’ effectiveness in treating cardiovascular diseases, GvHD, and brain and neurological disorders, although some trials sought to treat immune system diseases and wounds and to restore tissue.